



## FOR IMMEDIATE RELEASE

### Contacts:

#### For Ohmx Corporation:

Charles Rowland  
Tel: (847) 491-8508  
Fax: (847) 491-8510  
charles@ohmx.com

## Ohmx to present at AACC Oak Ridge

**Evanston IL, March 30<sup>th</sup> 2012** – Ohmx Corporation, a bioelectronic detection company focused on developing a near-patient analyzer for monitoring of chronic diseases, is pleased to announce that it will be presenting a poster at the 2012 AACC Oak Ridge Conference. The Oak Ridge Conference is the American Association for Clinical Chemistry's annual forum for emerging clinical diagnostic technologies. The conference will be held at The Fairmont in San José, Calif. on Thursday April 19<sup>th</sup> and Friday April 20<sup>th</sup> 2012.

### Poster Abstract:

#### **Bioelectronic Platform for Sensitive and Versatile Diagnostic Applications**

Ohmx Corporation

Ohmx is applying a novel redox construct on a disposable chip to detect multiple target analytes using a POC device. This versatile platform converts bio-molecular target recognition events to an electrochemically active product, which in turn generates an electro-catalytic signal on the chip coated with a self-assembled monolayer (SAM). This technology is applicable for ultrasensitive detection of proteins, such as Hemoglobin A1c (A1C) and Thyroid Stimulating Hormone (TSH), and small molecules such as Flavin Adenine Dinucleotide (FAD), lipid panel, nucleic acids and other targets.

For **A1C**, we have established a rapid quantitative assay based on an innovative single measurement approach for measuring this diabetic marker. Currently, the total assay time of the A1C test is <7 minutes with a linear response for A1C percentages ranging from 2% to 11%. The self-calibrated signal improves the assay's reproducibility, with CV normally less than 5% for low A1C percentages and less than 10% for high A1C percentages.

**Ultrasensitive protein assay** for Thyroid-Stimulating Hormone (TSH) detection has been demonstrated using the bioelectronic platform. The tests on serum samples demonstrate the specificity and the sensitivity of the TSH electrochemical assay. The TSH target titration shows the LOD <0.005  $\mu$ IU/mL with a dynamic range of more than 3 logs and CV <7%.

**High sensitivity small molecule assay** for Flavin Adenine Dinucleotide (FAD), a redox cofactor which plays an important role in metabolism, has been measured using the Ohmx platform. The functionality of the FAD assay is confirmed with serum samples and tumor cell line lysates. The FAD detection has a broad dynamic range of more than 3 logs, with CV <5% and an LOD of <0.003 nM, which is 100-fold more sensitive than existing commercial assay kits.

This platform provides a broad application for measuring multiple targets on a single disposable biochip using a portable bioelectronic device. The highly sensitive electrochemical platform also has potential applications in metabolomics, genomics and proteomics.

---

**About the Company:**

Ohmx is advancing e-Diagnostics by developing a POC device that can quantify clinical biomarkers and other important disease indicators from a finger stick. Ohmx's handheld monitoring device will be electronic, low-cost, user-friendly, and used as a near-patient analyzer in the convenience of the patient's home. Except for diabetes, there are few consumer devices that can monitor chronic diseases. Ohmx was founded by NU Prof. Thomas Meade, PhD, who sold his prior company to Motorola for \$300MM; President & CEO is Charles Rowland (Baxter, LifeWatch, Sirtex, ICS), R&D is headed by Dimitra Georganopoulou, Ph.D. (Inverness, Nanosphere) and Product Development is headed by Paul Bao, Ph.D. (Vysis, Corning, Nanosphere).

*This press release contains forward-looking statements that involve a number of risks and uncertainties. Our actual results could differ materially from the results identified or implied in any forward-looking statement. These statements are based on our views as of the date they are made with respect to future results or events. The Company does not undertake to publicly update or revise its forward-looking statements even if experience or future changes make it clear that any projected results or events expressed or implied therein will not be realized.*